@article{332156feb48a4681b2d3bf70daaa1203,
title = "Should Secondary Cytoreduction Be Used in Recurrent Ovarian Cancer?",
author = "Westin, {Shannon N.}",
note = "Funding Information: Dr Westin has received grants from AstraZeneca, Bayer, Bio-Path, Caris, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo BioPharma, Novartis, OncXerna Therapeutics, Roche/Genentech, and Zentalis Pharmaceuticals. She has received consulting fees from AstraZeneca, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics, Vincerx Pharma, and Zentalis Pharmaceuticals.",
year = "2022",
month = apr,
language = "English (US)",
volume = "20",
pages = "215--217",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "4",
}